

Product Data Sheet

Product Name: PROTAC BCL6 Degradar-2

Cat. No.: GC79419

Chemical Properties

Cas. No.


Formula C₄₆H₅₂ClN₁₁O₈ M.Wt 922.43

Solubility DMSO: 100 mg/mL (108.41 mM; Need ultrasonic) Storage Store at -20°C

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure



Background

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

PROTAC BCL6 Degradar-2 is an orally active, selective BCL6 PROTAC degrader (DC₅₀: 0.45 nM in HEK293T cells). PROTAC BCL6 Degradar-2 promotes ubiquitination and degradation of BCL6. It exhibits anticancer activity against BCL6-dependent diffuse large B-cell lymphoma. PROTAC BCL6 Degradar-2 can be used for the research of diffuse large B-cell lymphoma [1]. (Pink: BCL6 ligand; Blue: Cereblon ligand; Black: linker).

In Vivo, PROTAC BCL6 Degradar-2 (50 mg/kg; p.o.; daily; 17 days) achieves 37.2% tumor growth inhibition and reduces BCL6 protein levels in OCI-LY1 DLBCL xenografts in NOD-SCID mice without obvious toxicity[1].

In Vitro, PROTAC BCL6 Degradar-2 (Compound A19) (0.001-100 nM; 24 h) potently degrades BCL6 in HEK293T cells stably expressing BCL6-GFP, with a DC₅₀ of 0.45 nM and a maximum degradation rate of up to 94.60% at a concentration of 100 nM[1]. PROTAC BCL6 Degradar-2 (0.001-100 nM; 0-24 h) potently and rapidly degrades BCL6 in OCI-LY1 diffuse large B-cell lymphoma (DLBCL) cells, with a DC₅₀ of 0.034 nM, a maximum degradation rate of >99% at 24 h, and complete degradation achieved within 1 h at a concentration of 40 nM[1]. PROTAC BCL6 Degradar-2 (10 nM; 6 h) selectively degrades BCL6 in OCI-LY1 diffuse large B-cell lymphoma (DLBCL) cells, with no effect on the novel CRBN substrates IKZF1, IKZF2, IKZF3 or GSPT1[1]. PROTAC BCL6 Degradar-2 (7 days) potently inhibits the proliferation of OCI-LY1 diffuse large B-cell lymphoma (DLBCL) cells, with an IC₅₀ value of 12.78 nM[1]. PROTAC BCL6 Degradar-2 (7 days) inhibits the growth of BCL6-dependent HT, SU-DHL4 and OCI-LY10 diffuse large B-cell lymphoma (DLBCL) cells, with corresponding IC₅₀ values of 36.30 nM, 500.00 nM and 835.33 nM, but shows no activity in BCL6-independent Toledo DLBCL cells[1].

References:

[1]. Yu X, et al. Discovery of a Selective and Potent BCL6 PROTAC with Efficacious Antiproliferative Activity for the Treatment of Diffuse Large B-Cell Lymphoma. Journal of medicinal chemistry. 2025 Oct 09;68(19):20180-20206.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA